CTOs on the Move

Children's Crisis Treatment Center

www.cctckids.org

 
CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.cctckids.org
  • 1080, North Delaware Avenue
    Philadelphia, PA USA 19125
  • Phone: 215.496.0707

Executives

Name Title Contact Details

Similar Companies

Wilmington Pharmaceuticals

Wilmington Pharmaceuticals is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Resau Medisca Network

Resau Medisca Network Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acreage Holdings

Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company`s national retail store ‎brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ‎seamless, consumer-focused, branded experience.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

VersaPharm Incorporated

VersaPharm Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.